Medexus Announces Strong Fiscal Q2 2027 Results Driven By Record Product-Level Performance of GRAFAPEX (Treosulfan) for Injection

Fiscal Q2 2027 net revenue of $29.1 million, Adjusted EBITDA* of $5.1 million, operating income of $2.4 million, and net income of $0.8 million - all quarterly records since fiscal Q4 2025, demonstrating significant year-over-year growthProduct-level net revenue* from GRAFAPEX™ (treosulfan) for Inj…